65,437 trials
Ventricular Tachycardia · Ventricular Fibrillation · Atrial Fibrillation
Primary: Number of Subjects Inappropriately Shocked by Implantable Cardioverter-Defibrillator (ICD) — 1; 1 Participants — p=1.0
Rheumatoid Arthritis
Primary: Serum Concentrations of Adalimumab at Weeks 12 and 24 — 5.72; 6.23; 5.95; 6.17 µg/mL
Post-operative Pain
Primary: The Postoperative Opioid Requirement After Mastectomy — 9; 7.5 milligram (mg)
Lipid Metabolism Disorders
Primary: Mean Percent Change in LDL-C From Baseline at Study Endpoint, Week 12 (LOCF) — -8.692; -7.887 Percent change
Congenital Bleeding Disorder · Haemophilia A
Primary: The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU)) — 0 N with Inhibitors / N with ≥50 EDs
Asthma
Primary: Trough FEV1 Response After 4 Weeks — 0.004; 0.083; 0.090; 0.080 Liter — p=0.0754
Type 2 Diabetes
Primary: Mean AM BG (mg/dl) — 144; 155 mg/dl
Healthy
Primary: Serum Estradiol Levels by Cycle Day — 47.00; 51.50; 62.50; 34.50 pg/mL — p=0.6346
Rheumatoid Arthritis
Primary: Percentage of Participants With Low Disease Activity Score at Week 24 — 57 Percentage of Participants — p=<0.001
Lupus Erythematosus, Systemic
Primary: Relapse-free Complete Clinical Response — 54 Months
Scleritis
Primary: Number of Participants Who Experience at Least 2-step Reduction or Reduction to Grade 0 of Scleral Inflammation in the Study Eye According to the National Eye Institute…
Pulmonary Disease, Chronic Obstructive
Primary: Trough FEV1 Response at Week 4 — -0.032; 0.059; 0.100; 0.100 Liter — p=<0.0001
Healthy · Pulmonary Disease, Chronic Obstructive
Primary: Area Under Curve From 0 to 6 Hours at Steady State (AUC0-6,ss) — 19.659; 22.271 Picogram*hours/milliliter — p=0.0101
Retinopathy of Prematurity
Primary: Regression of Retinopathy of Prematurity (ROP) in Premature Infants by Propranolol Therapy — 4; 8 cases
Rheumatoid Arthritis
Primary: Percentage of Participants With an Adverse Event (AE) — 26.7 percentage of participants